1
|
Szupryczyński K, Czeleń P, Jeliński T, Szefler B. What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review. Int J Nanomedicine 2024; 19:9503-9547. [PMID: 39296940 PMCID: PMC11410046 DOI: 10.2147/ijn.s469217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2024] [Accepted: 07/19/2024] [Indexed: 09/21/2024] Open
Abstract
Over the course of several decades, anticancer treatment with chemotherapy drugs for lung cancer has not changed significantly. Unfortunately, this treatment prolongs the patient's life only by a few months, causing many side effects in the human body. It has also been proven that drugs such as Cisplatin, Carboplatin, Oxaliplatin and others can react with other substances containing an aromatic ring in which the nitrogen atom has a free electron group in its structure. Thus, such structures may have a competitive effect on the nucleobases of DNA. Therefore, scientists are looking not only for new drugs, but also for new alternative ways of delivering the drug to the cancer site. Nanotechnology seems to be a great hope in this matter. Creating a new nanomedicine would reduce the dose of the drug to an absolute minimum, and thus limit the toxic effect of the drug; it would allow for the exclusion of interactions with competitive compounds with a structure similar to nucleobases; it would also permit using the so-called targeted treatment and bypassing healthy cells; it would allow for the introduction of other treatment options, such as radiotherapy directly to the cancer site; and it would provide diagnostic possibilities. This article is a review that aims to systematize the knowledge regarding the anticancer treatment of lung cancer, but not only. It shows the clear possibility of interactions of chemotherapeutics with compounds competitive to the nitrogenous bases of DNA. It also shows the possibilities of using nanostructures as potential Platinum drug carriers, and proves that nanomedicine can easily become a new medicinal product in personalized medicine.
Collapse
Affiliation(s)
- Kamil Szupryczyński
- Doctoral School of Medical and Health Sciences, Faculty of Pharmacy, Collegium Medicum, Nicolaus, Copernicus University, Bydgoszcz, Poland
| | - Przemysław Czeleń
- Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
| | - Tomasz Jeliński
- Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
| | - Beata Szefler
- Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
| |
Collapse
|
2
|
Deilam M, Ghasemi AS. Assessment of drug loading and release efficiencies of zigzag (8, 0) single-walled carbon nanotube as a Bendamustine hydrochloride drug delivery system in silico: DFT approach. MOLECULAR SIMULATION 2021. [DOI: 10.1080/08927022.2021.2009120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Mehri Deilam
- Department of Chemistry, Payame Noor University, Tehran, Iran
| | | |
Collapse
|
3
|
Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. Int J Nanomedicine 2021; 16:1313-1330. [PMID: 33628022 PMCID: PMC7898224 DOI: 10.2147/ijn.s289443] [Citation(s) in RCA: 115] [Impact Index Per Article: 38.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 12/23/2020] [Indexed: 12/12/2022] Open
Abstract
Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors' clinical management. This review describes nanocarrier's importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented.
Collapse
Affiliation(s)
- Zehra Edis
- Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
- Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
| | - Junli Wang
- Laboratory of Reproduction and Genetics, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, People’s Republic of China
| | - Muhammad Khurram Waqas
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - Muhammad Ijaz
- Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, Pakistan
| | - Munazza Ijaz
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Defense Road Campus, Lahore, Pakistan
| |
Collapse
|
4
|
Salas-Treviño D, Saucedo-Cárdenas O, Loera-Arias MDJ, Rodríguez-Rocha H, García-García A, Montes-de-Oca-Luna R, Piña-Mendoza EI, Contreras-Torres FF, García-Rivas G, Soto-Domínguez A. Hyaluronate Functionalized Multi-Wall Carbon Nanotubes Filled with Carboplatin as a Novel Drug Nanocarrier against Murine Lung Cancer Cells. NANOMATERIALS (BASEL, SWITZERLAND) 2019; 9:E1572. [PMID: 31698759 PMCID: PMC6915394 DOI: 10.3390/nano9111572] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 10/23/2019] [Accepted: 10/26/2019] [Indexed: 12/21/2022]
Abstract
Carbon nanotubes (CNTs) have emerged in recent years as a potential option for drug delivery, due to their high functionalization capacity. Biocompatibility and selectivity using tissue-specific biomolecules can optimize the specificity, pharmacokinetics and stability of the drug. In this study, we design, develop and characterize a drug nanovector (oxCNTs-HA-CPT) conjugating oxidated multi-wall carbon nanotubes (oxCNTs) with hyaluronate (HA) and carboplatin (CPT) as a treatment in a lung cancer model in vitro. Subsequently, we exposed TC-1 and NIH/3T3 cell lines to the nanovectors and measured cell uptake, cell viability, and oxidative stress induction. The characterization of oxCNTs-HA-CPT reveals that on their surface, they have HA. On the other hand, oxCNTs-HA-CPT were endocytosed in greater proportion by tumor cells than by fibroblasts, and likewise, the cytotoxic effect was significantly higher in tumor cells. These results show the therapeutic potential that nanovectors possess; however, future studies should be carried out to determine the death pathways involved, as well as their effect on in vivo models.
Collapse
Affiliation(s)
- Daniel Salas-Treviño
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | - Odila Saucedo-Cárdenas
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
- Departamento de Genética Molecular, Centro de Investigación Biomédica del Noreste (CIBIN) del IMSS, Monterrey C.P. 64720, Mexico
| | - María de Jesús Loera-Arias
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | - Humberto Rodríguez-Rocha
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | - Aracely García-García
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | - Roberto Montes-de-Oca-Luna
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | - Edgar I. Piña-Mendoza
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| | | | | | - Adolfo Soto-Domínguez
- Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey C.P. 64460, Mexico; (D.S.-T.); (O.S.-C.); (M.d.J.L.-A.); (H.R.-R.); (A.G.-G.); (R.M.-d.-O.-L.); (E.I.P.-M.)
| |
Collapse
|
5
|
Sharma S, Naskar S, Kuotsu K. A review on carbon nanotubes: Influencing toxicity and emerging carrier for platinum based cytotoxic drug application. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.02.028] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Xiao H, Yan L, Dempsey EM, Song W, Qi R, Li W, Huang Y, Jing X, Zhou D, Ding J, Chen X. Recent progress in polymer-based platinum drug delivery systems. Prog Polym Sci 2018. [DOI: 10.1016/j.progpolymsci.2018.07.004] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
7
|
Virani NA, Davis C, McKernan P, Hauser P, Hurst RE, Slaton J, Silvy RP, Resasco DE, Harrison RG. Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer. NANOTECHNOLOGY 2018; 29:035101. [PMID: 29160225 DOI: 10.1088/1361-6528/aa9c0c] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Bladder cancer has a 60%-70% recurrence rate most likely due to any residual tumour left behind after a transurethral resection (TUR). Failure to completely resect the cancer can lead to recurrence and progression into higher grade tumours with metastatic potential. We present here a novel therapy to treat superficial tumours with the potential to decrease recurrence. The therapy is a heat-based approach in which bladder tumour specific single-walled carbon nanotubes (SWCNTs) are delivered intravesically at a very low dose (0.1 mg SWCNT per kg body weight) followed 24 h later by a short 30 s treatment with a 360° near-infrared light that heats only the bound nanotubes. The energy density of the treatment was 50 J cm-2, and the power density that this treatment corresponds to is 1.7 W cm-2, which is relatively low. Nanotubes are specifically targeted to the tumour via the interaction of annexin V (AV) and phosphatidylserine, which is normally internalised on healthy tissue but externalised on tumours and the tumour vasculature. SWCNTs are conjugated to AV, which binds specifically to bladder cancer cells as confirmed in vitro and in vivo. Due to this specific localisation, NIR light can be used to heat the tumour while conserving the healthy bladder wall. In a short-term efficacy study in mice with orthotopic MB49 murine bladder tumours treated with the SWCNT-AV conjugate and NIR light, no tumours were visible on the bladder wall 24 h after NIR light treatment, and there was no damage to the bladder. In a separate survival study in mice with the same type of orthotopic tumours, there was a 50% cure rate at 116 days when the study was ended. At 116 days, no treatment toxicity was observed, and no nanotubes were detected in the clearance organs or bladder.
Collapse
Affiliation(s)
- Needa A Virani
- School of Biomedical Engineering, University of Oklahoma, 202 W. Boyd Street, Norman, OK 73019, United States of America
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sheader AA, Varambhia AM, Fleck RA, Flatters SJL, Nellist PD. Observation of metal nanoparticles at atomic resolution in Pt-based cancer chemotherapeutics. J Microsc 2017; 270:92-97. [PMID: 29091266 DOI: 10.1111/jmi.12659] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 09/26/2017] [Indexed: 11/29/2022]
Abstract
The chemotherapeutics cisplatin and oxaliplatin are important tools in the fight against cancer. Both compounds are platinum complexes. Aberration-corrected scanning transmission electron microscopy using the annular dark-field imaging mode now routinely provides single-atom sensitivity with atomic number contrast. Here, this imaging mode is used to directly image the platinum within the two drugs in their dried form on an amorphous carbon support film. The oxaliplatin is found to have wetted the supporting amorphous carbon, forming disordered clusters suggesting that the platinum has remained within the complex. Conversely, the cisplatin sample reveals 1.8-nm-diameter metallic platinum clusters. The size and shape of the clusters do not appear to be dependent on drying rate nor formed by beam damage, which may suggest that they were present in the original drug solution.
Collapse
Affiliation(s)
- A A Sheader
- Department of Materials, University of Oxford, Oxford, U.K
| | - A M Varambhia
- Department of Materials, University of Oxford, Oxford, U.K
| | - R A Fleck
- Centre for Ultrastructural Imaging, Kings College London, London, U.K
| | - S J L Flatters
- Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, U.K
| | - P D Nellist
- Department of Materials, University of Oxford, Oxford, U.K
| |
Collapse
|
9
|
Abstract
Carbon nanotubes (CNTs) have received increasing attention in biomedical fields because of their unique structures and properties, including high aspect ratios, large surface areas, rich surface chemical functionalities, and size stability on the nanoscale. Particularly, they are attractive as carriers and mediators for cancer therapy. Through appropriate functionalization, CNTs have been used as nanocarriers for anticancer drugs including doxorubicin, camptothecin, carboplatin, cisplatin, paclitaxel, Pt(II), and Pt(IV), and genes including plasmid DNA, small-interfering RNA, oligonucleotides, and RNA/DNA aptamers. CNTs can also deliver proteins and immunotherapy components. Using combinations of light energy, they have also been applied as mediators for photothermal therapy and photodynamic therapy to directly destroy cancer cells without severely damaging normal tissue. If limitations such as a long-term cytotoxicity in the body, lack of size uniformity during the synthetic process, loading deviations for drug–CNT complexes, and release controllability at the target point are overcome, CNTs will become one of the strongest tools that are available for various other biomedical fields as well as for cancer therapy.
Collapse
Affiliation(s)
- Kuk Hui Son
- Department of Thoracic and Cardiovascular Surgery, Gachon University Gil Medical Center
| | | | - Jin Woo Lee
- Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea
| |
Collapse
|
10
|
Nowacki M, Wisniewski M, Werengowska-Ciecwierz K, Roszek K, Czarnecka J, Łakomska I, Kloskowski T, Tyloch D, Debski R, Pietkun K, Pokrywczynska M, Grzanka D, Czajkowski R, Drewa G, Jundziłł A, Agyin JK, Habib SL, Terzyk AP, Drewa T. Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis. Oncotarget 2015; 6:22776-98. [PMID: 26254295 PMCID: PMC4673199 DOI: 10.18632/oncotarget.4309] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 05/13/2015] [Indexed: 12/12/2022] Open
Abstract
In general, detection of peritoneal carcinomatosis (PC) occurs at the late stage when there is no treatment option. In the present study, we designed novel drug delivery systems that are functionalized with anti-CD133 antibodies. The C1, C2 and C3 complexes with cisplatin were introduced into nanotubes, either physically or chemically. The complexes were reacted with anti-CD133 antibody to form the labeled product of A0-o-CX-chem-CD133. Cytotoxicity screening of all the complexes was performed on CHO cells. Data showed that both C2 and C3 Pt-complexes are more cytotoxic than C1. Flow-cytometry analysis showed that nanotubes conjugated to CD133 antibody have the ability to target cells expressing the CD133 antigen which is responsible for the emergence of resistance to chemotherapy and disease recurrence. The shortest survival rate was observed in the control mice group (K3) where no hyperthermic intraperitoneal chemotherapy procedures were used. On the other hand, the longest median survival rate was observed in the group treated with A0-o-C1-chem-CD133. In summary, we designed a novel drug delivery system based on carbon nanotubes loaded with Pt-prodrugs and functionalized with anti-CD133 antibodies. Our data demonstrates the effectiveness of the new drug delivery system and provides a novel therapeutic modality in the treatment of melanoma.
Collapse
Affiliation(s)
- Maciej Nowacki
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
| | - Marek Wisniewski
- Physicochemistry of Carbon Materials Research Group, Faculty of Chemistry, Nicolaus Copernicus University in Torun, Poland
- Invest-Tech, Research and Development Center, Torun, Poland
| | - Karolina Werengowska-Ciecwierz
- Physicochemistry of Carbon Materials Research Group, Faculty of Chemistry, Nicolaus Copernicus University in Torun, Poland
| | - Katarzyna Roszek
- Department of Biochemistry, Faculty of Biology and Environment Protection, Nicolaus Copernicus University in Torun, Poland
| | - Joanna Czarnecka
- Department of Biochemistry, Faculty of Biology and Environment Protection, Nicolaus Copernicus University in Torun, Poland
| | - I. Łakomska
- Faculty of Chemistry, Nicolaus Copernicus University in Torun, Poland
| | - Tomasz Kloskowski
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
| | - Dominik Tyloch
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
| | - Robert Debski
- Department of Pediatric Hematology and Oncology, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Torun, Poland
| | - Katarzyna Pietkun
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
- Chair of Dermatology Department, Faculty of Medicine, Nicolaus Copernicus University, Toruń, Sexually Transmitted Diseases and Immunodermatology, Bydgoszcz, Poland
| | - Marta Pokrywczynska
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
| | - Dariusz Grzanka
- Chair of Dermatology Department, Faculty of Medicine, Nicolaus Copernicus University, Toruń, Sexually Transmitted Diseases and Immunodermatology, Bydgoszcz, Poland
| | - Rafał Czajkowski
- Chair of Dermatology Department, Faculty of Medicine, Nicolaus Copernicus University, Toruń, Sexually Transmitted Diseases and Immunodermatology, Bydgoszcz, Poland
| | - Gerard Drewa
- Department of Medical Biology, University of Bydgoszcz, Poland
| | - A. Jundziłł
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
| | - Joseph K. Agyin
- Department of Biochemistry, The University of Texas Health Science Center, San Antonio, TX, USA
| | - Samy L. Habib
- Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA
- Department of Geriatric, South Texas Veterans Health System, The University of Texas Health Science Center, San Antonio, TX, USA
| | - Artur P. Terzyk
- Physicochemistry of Carbon Materials Research Group, Faculty of Chemistry, Nicolaus Copernicus University in Torun, Poland
| | - Tomasz Drewa
- Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier's Collegium Medicum in Bydgoszcz Nicolaus Copernicus University, Torun, Poland
- Urology Department, Nicolaus Copernicus Hospital in Torun, Torun, Poland
| |
Collapse
|
11
|
Nowacki M, Wiśniewski M, Werengowska-Ciećwierz K, Terzyk AP, Kloskowski T, Marszałek A, Bodnar M, Pokrywczyńska M, Nazarewski Ł, Pietkun K, Jundziłł A, Drewa T. New application of carbon nanotubes in haemostatic dressing filled with anticancer substance. Biomed Pharmacother 2014; 69:349-54. [PMID: 25661381 DOI: 10.1016/j.biopha.2014.12.033] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Accepted: 12/11/2014] [Indexed: 12/13/2022] Open
Abstract
The drug-carrier system used as innovative haemostatic dressing with oncostatic action is studied. It is obtained from CDDP (cisplatin) doped SWCNT (single walled carbon nanotubes), modified and purified by H2O2 in hydrothermal treatment process. In the in vivo nephron sparing surgery (NSS) study we used 35 BALB/c nude mice with induced renal cancer using adenocarcinoma 786-o cells. Animals were divided into four groups: CDDP(M-), CDDP(M+), CONTROL(M-) and CONTROL(M+). In CDDP(M-) and CDDP(M+) groups we used, intraoperatively, carbon nanotubes filled with cisplatin (CDDP). In CONTROL(M-) and CONTROL(M+) groups carbon nanotubes were used alone. During NSS free margin (M-) or positive margin (M+) was performed. In the CDDP(M-) group, we do not observe local tumor recurrences. In Group CDDP(M+) only one animal was diagnosed with tumor recurrence. In control groups the recurrent tumor formation was observed. In our study, it is shown that CDDP filled SWCNT inhibit cancer recurrence in animal model NSS study, and can be successfully applied as haemostatic dressings for local chemoprevention.
Collapse
Affiliation(s)
- M Nowacki
- N. Copernicus University, Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Karłowicza St. 24, 85-092 Bydgoszcz, Poland
| | - M Wiśniewski
- N. Copernicus University, Department of Chemistry, Physicochemistry of Carbon Materials Research Group, Gagarin St. 7, 87-100 Toruń, Poland
| | - K Werengowska-Ciećwierz
- N. Copernicus University, Department of Chemistry, Physicochemistry of Carbon Materials Research Group, Gagarin St. 7, 87-100 Toruń, Poland
| | - A P Terzyk
- N. Copernicus University, Department of Chemistry, Physicochemistry of Carbon Materials Research Group, Gagarin St. 7, 87-100 Toruń, Poland.
| | - T Kloskowski
- N. Copernicus University, Department of Clinical Pathomorphology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Jagiellońska 13-15, 85-067 Bydgoszcz, Poland
| | - A Marszałek
- Medical University of Warsaw, Department of General, Transplant and Liver Surgery, Banacha 1a, 02-097 Warsaw, Poland
| | - M Bodnar
- Medical University of Warsaw, Department of General, Transplant and Liver Surgery, Banacha 1a, 02-097 Warsaw, Poland
| | - M Pokrywczyńska
- N. Copernicus University, Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Karłowicza St. 24, 85-092 Bydgoszcz, Poland
| | - Ł Nazarewski
- N. Copernicus Hospital, Urology and Oncological Urology Department, Batorego St. 17/19, 87-100 Toruń, Poland
| | - K Pietkun
- N. Copernicus University, Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Karłowicza St. 24, 85-092 Bydgoszcz, Poland
| | - A Jundziłł
- N. Copernicus University, Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Karłowicza St. 24, 85-092 Bydgoszcz, Poland
| | - T Drewa
- N. Copernicus University, Chair of Regenerative Medicine, Tissue Engineering Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Karłowicza St. 24, 85-092 Bydgoszcz, Poland; N. Copernicus Hospital, Urology and Oncological Urology Department, Batorego St. 17/19, 87-100 Toruń, Poland
| |
Collapse
|
12
|
Abstract
Current first-line treatments for most cancers feature a short-list of highly potent and often target-blind interventions, including chemotherapy, radiation, and surgical excision. These treatments wreak considerable havoc upon non-cancerous tissue and organs, resulting in deleterious and sometimes fatal side effects for the patient. In response, this past decade has witnessed the robust emergence of nanoparticles and, more relevantly, nanoparticle drug delivery systems (DDS), widely touted as the panacea of cancer therapeutics. While not a cure, nanoparticle DDS can successfully negotiate the clinical payoff between drug dosage and side effects by encompassing target-specific drug delivery strategies. The expanding library of nanoparticles includes lipoproteins, liposomes, dendrimers, polymers, metal and metal oxide nano-spheres and -rods, and carbon nanotubes, so do the modes of delivery. Importantly, however, the pharmaco-dynamics and –kinetics of these nano-complexes remain an urgent issue and a serious bottleneck in the transition from bench to bedside. This review addresses the rise of nanoparticle DDS platforms for cancer and explores concepts of gene/drug delivery and cytotoxicity in pre-clinical and clinical contexts.
Collapse
|
13
|
Wong BS, Yoong SL, Jagusiak A, Panczyk T, Ho HK, Ang WH, Pastorin G. Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev 2013; 65:1964-2015. [PMID: 23954402 DOI: 10.1016/j.addr.2013.08.005] [Citation(s) in RCA: 326] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2013] [Revised: 08/01/2013] [Accepted: 08/05/2013] [Indexed: 11/30/2022]
Abstract
In the realm of drug delivery, carbon nanotubes (CNTs) have gained tremendous attention as promising nanocarriers, owing to their distinct characteristics, such as high surface area, enhanced cellular uptake and the possibility to be easily conjugated with many therapeutics, including both small molecules and biologics, displaying superior efficacy, enhanced specificity and diminished side effects. While most CNT-based drug delivery system (DDS) had been engineered to combat cancers, there are also emerging reports that employ CNTs as either the main carrier or adjunct material for the delivery of various non-anticancer drugs. In this review, the delivery of small molecule drugs is expounded, with special attention paid to the current progress of in vitro and in vivo research involving CNT-based DDSs, before finally concluding with some consideration on inevitable complications that hamper successful disease intervention with CNTs.
Collapse
Affiliation(s)
- Bin Sheng Wong
- Department of Pharmacy, National University of Singapore, S4 Science Drive 4, Singapore 117543, Singapore.
| | | | | | | | | | | | | |
Collapse
|
14
|
Singh R, Torti SV. Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev 2013; 65:2045-60. [PMID: 23933617 DOI: 10.1016/j.addr.2013.08.001] [Citation(s) in RCA: 135] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Revised: 07/31/2013] [Accepted: 08/01/2013] [Indexed: 01/17/2023]
Abstract
Thermal tumor ablation therapies are being developed with a variety of nanomaterials, including single- and multiwalled carbon nanotubes. Carbon nanotubes (CNTs) have attracted interest due to their potential for simultaneous imaging and therapy. In this review, we highlight in vivo applications of carbon nanotube-mediated thermal therapy (CNMTT) and examine the rationale for use of this treatment in recurrent tumors or those resistant to conventional cancer therapies. Additionally, we discuss strategies to localize and enhance the cancer selectivity of this treatment and briefly examine issues relating the toxicity and long term fate of CNTs.
Collapse
|
15
|
|
16
|
Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine 2011; 6:2963-79. [PMID: 22162655 PMCID: PMC3230565 DOI: 10.2147/ijn.s16923] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Cancer is a generic term that encompasses a group of diseases characterized by an uncontrolled proliferation of cells. There are over 200 different types of cancer, each of which gains its nomenclature according to the type of tissue the cell originates in. Many patients who succumb to cancer do not die as a result of the primary tumor, but because of the systemic effects of metastases on other regions away from the original site. One of the aims of cancer therapy is to prevent the metastatic process as early as possible. There are currently many therapies in clinical use, and recent advances in biotechnology lend credence to the potential of nanotechnology in the fight against cancer. Nanomaterials such as carbon nanotubes (CNTs), quantum dots, and dendrimers have unique properties that can be exploited for diagnostic purposes, thermal ablation, and drug delivery in cancer. CNTs are tubular materials with nanometer-sized diameters and axial symmetry, giving them unique properties that can be exploited in the diagnosis and treatment of cancer. In addition, CNTs have the potential to deliver drugs directly to targeted cells and tissues. Alongside the rapid advances in the development of nanotechnology-based materials, elucidating the toxicity of nanoparticles is also imperative. Hence, in this review, we seek to explore the biomedical applications of CNTs, with particular emphasis on their use as therapeutic platforms in oncology.
Collapse
Affiliation(s)
- Seyed Yazdan Madani
- Centre for Nanotechnology and Regenerative Medicine, Division of Surgery and Interventional Sciences, University College London, UK
| | | | | | | | | |
Collapse
|
17
|
Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD, Gutkind JS, Lee S, Chen X. Combining portable Raman probes with nanotubes for theranostic applications. Am J Cancer Res 2011; 1:310-21. [PMID: 21769298 PMCID: PMC3137983 DOI: 10.7150/thno/v01p0310] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Accepted: 07/04/2011] [Indexed: 02/06/2023] Open
Abstract
Recently portable Raman probes have emerged along with a variety of applications, including carbon nanotube (CNT) characterization. Aqueous dispersed CNTs have shown promise for biomedical applications such as drug/gene delivery vectors, photo-thermal therapy, and photoacoustic imaging. In this study we report the simultaneous detection and irradiation of carbon nanotubes in 2D monolayers of cancer cells and in 3D spheroids using a portable Raman probe. A portable handheld Raman instrument was utilized for dual purposes: as a CNT detector and as an irradiating laser source. Single-walled carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs) were dispersed aqueously using a lipid-polymer (LP) coating, which formed highly stable dispersions both in buffer and cell media. The LP coated SWCNT and MWCNT aqueous dispersions were characterized by atomic force microscopy, transmission electron microscopy, dynamic light scattering, Fourier transform infrared spectroscopy and Raman spectroscopy. The cellular uptake of the LP-dispersed SWCNTs and MWCNTs was observed using confocal microscopy, and fluorescein isothiocyanate (FITC)-nanotube conjugates were found to be internalized by ovarian cancer cells by using Z-stack fluorescence confocal imaging. Biocompatibility of SWCNTs and MWCNTs was assessed using a cell viability MTT assay, which showed that the nanotube dispersions did not hinder the proliferation of ovarian cancer cells at the dosage tested. Ovarian cancer cells treated with SWCNTs and MWCNTs were simultaneously detected and irradiated live in 2D layers of cancer cells and in 3D environments using the portable Raman probe. An apoptotic terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay carried out after laser irradiation confirmed that cell death occurred only in the presence of nanotube dispersions. We show for the first time that both SWCNTs and MWCNTs can be selectively irradiated and detected in cancer cells using a simple handheld Raman instrument. This approach could potentially be used to treat various diseases, including cancer.
Collapse
|
18
|
Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD, Gutkind JS, Rusling JF. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond) 2010; 5:1535-46. [PMID: 21143032 PMCID: PMC3175610 DOI: 10.2217/nnm.10.90] [Citation(s) in RCA: 132] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
AIMS To study the distribution and clearance of polyethylene glycol (PEG)-ylated single-walled carbon nanotube (SWCNTs) as drug delivery vehicles for the anticancer drug cisplatin in mice. MATERIALS & METHODS PEG layers were attached to SWCNTs and dispersed in aqueous media and characterized using dynamic light scattering, scanning transmission electron microscopy and Raman spectroscopy. Cytotoxicity was assessed in vitro using Annexin-V assay, and the distribution and clearance pathways in mice were studied by histological staining and Raman spectroscopy. Efficacy of PEG-SWCNT-cisplatin for tumor growth inhibition was studied in mice. RESULTS & DISCUSSION PEG-SWCNTs were efficiently dispersed in aqueous media compared with controls, and did not induce apoptosis in vitro. Hematoxylin and eosin staining, and Raman bands for SWCNTs in tissues from several vital organs from mice injected intravenously with nanotube bioconjugates revealed that control SWCNTs were lodged in lung tissue as large aggregates compared with the PEG-SWCNTs, which showed little or no accumulation. Characteristic SWCNT Raman bands in feces revealed the presence of bilary or renal excretion routes. Attachment of cisplatin on bioconjugates was visualized with Z-contrast scanning transmission electron microscopy. PEG-SWCNT-cisplatin with the attached targeting ligand EGF successfully inhibited growth of head and neck tumor xenografts in mice. CONCLUSIONS PEG-SWCNTs, as opposed to control SWCNTs, form more highly dispersed delivery vehicles that, when loaded with both cisplatin and EGF, inhibit growth of squamous cell tumors.
Collapse
Affiliation(s)
- Ashwin A Bhirde
- Department of Chemistry, University of Connecticut, Storrs, CT, USA
| | - Sachin Patel
- Oral & Pharyngeal Cancer Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Alioscka A Sousa
- Laboratory of Cellular Imaging & Macromolecular Biophysics, National Institute of Biomedical Imaging & Bioengineering, NIH, Bethesda, MD 20892, USA
| | - Vyomesh Patel
- Oral & Pharyngeal Cancer Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Alfredo A Molinolo
- Oral & Pharyngeal Cancer Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Youngmi Ji
- Clinical & Experimental Orthopedics, National Institute of Arthritis, & Musculoskeletal & Skin Diseases, NIH, Bethesda, MD, USA
| | - Richard D Leapman
- Laboratory of Cellular Imaging & Macromolecular Biophysics, National Institute of Biomedical Imaging & Bioengineering, NIH, Bethesda, MD 20892, USA
| | - J Silvio Gutkind
- Oral & Pharyngeal Cancer Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - James F Rusling
- Department of Chemistry, University of Connecticut, Storrs, CT, USA
- Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA
- Institute of Materials Science, University of Connecticut, Storrs, CT, USA
| |
Collapse
|